Key result
A low-grade Khorana Score (KS = 0) demonstrated a negative predictive value of 95.4% for thromboembolic events during and up to 45 days after hospitalization in cancer patients.
Why the study?
Hospitalized cancer patients have an increased risk for thromboembolic events, and untailored thromboprophylaxis carries hemorrhagic risk, creating a need for a risk-assessment model.
Does the Khorana Score accurately predict the risk of thromboembolic events in hospitalized cancer patients?
Observational (n=535)
No
Does the Khorana Score accurately predict the risk of thromboembolic events in hospitalized cancer patients?
Effect estimate: NPV 95.4% (95% CI 90.8-98.1)
p-value: p=0.084
The Khorana Score has a high negative predictive value but poor positive predictive value for thromboembolic events in hospitalized cancer patients, prompting the development of a new risk assessment model.
No takes yet. Share an insight, caveat, or question.
High NPV of Khorana Score=0 may help exclude TE risk in hospitalized cancer patients; leaves open need for superior models given low PPV.
Nichetti et al. (2021) conducted an observational in Hospitalized cancer patients (n=535). Low-grade Khorana Score (KS = 0) vs. Higher-grade Khorana Score (KS ≥ 1) was evaluated on Negative Predictive Value (NPV) for thromboembolic events (NPV 95.4%, 95% CI 90.8-98.1, p=0.084). A low-grade Khorana Score (KS = 0) demonstrated a negative predictive value of 95.4% for thromboembolic events during and up to 45 days after hospitalization in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: